The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Golcadomide + Pola-RCHP in newly diagnosed aggressive B-cell lymphoma: safety and 12-month efficacy
In this video, Marc Hoffmann, MD, University of Kansas Medical Center, Kansas City, KS, shares the safety and 12-month efficacy results from a trial (NCT04884035) of golcadomide plus polatuzumab vedotin (Pola)-RCHP in patients with newly diagnosed aggressive B-cell lymphoma, highlighting that the addition of Pola improved efficacy without increasing toxicity. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the trial is actually a second portion of a much larger phase one effort that was looking at adding golcadamide to baseline anthracycline-based chemoimmunotherapy regimens for frontline large cell lymphoma. So the initial study was with RCHOP, and then with the approval of polatuzumab-vedotin, we decided to move forward with RCHP-POLA and add golcadamide to it. I think importantly, we saw very, very similar toxicity results...
So the trial is actually a second portion of a much larger phase one effort that was looking at adding golcadamide to baseline anthracycline-based chemoimmunotherapy regimens for frontline large cell lymphoma. So the initial study was with RCHOP, and then with the approval of polatuzumab-vedotin, we decided to move forward with RCHP-POLA and add golcadamide to it. I think importantly, we saw very, very similar toxicity results. So the frontline results were mainly related to toxicity. We saw the same MTD, the same recommended phase 2 dose, and there was no significant increase in terms of the cytopenia-related adverse events when you added the polatuzumab in and substituted it for the vincristine. We saw similarly high efficacy rates. So the complete response rate was 89% in both studies. The one-year or 12-month PFS in this particular study with RCHP plus polatuzumab was 96%. That in the RCHOP arm with a little longer follow-up at two years was 79%. So it does appear that there may be a little bit of an efficacy bump with the addition of polatuzumab and certainly not at the expense of any increased toxicities. I think the other important thing to highlight in the particular study is it confirmed that the 0.4 milligram dose of golcadamide does result in significantly higher efficacy compared to the 0.2 milligram dose. And so that dose is the dose that was chosen for the phase three that has now completed.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
